EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody i. the effect on image contrast in clinical studies






European Journal of Nuclear Medicine 11(8): 295-299

Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody i. the effect on image contrast in clinical studies

The poor imaging characteristics of 131I have resulted in the use of alternative radionuclides for radiolabelling monoclonal antibodies. Clinical imaging studies have shown that, in addition to the more suitable energy of emission of 111In over 131I for gamma camera detection, the 111In-labelled antibody appears to celar from the blood-stream at a faster rate than that of 131-labelled antibody, resulting in greater tumour-to-background image contrast. However, measurements of the activity in blood samples from patients demonstrate that both 131I- and 111In-labelled antibodies clear from the circulation at similar rate. This discrepancy is probably due to the different biological fates of the two radionuclides and warrants further scientific study.


Accession: 005151703

PMID: 4076237



Related references

Perkins, A.C.; Pimm, M.V., 1985: Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. I. The effect on image contrast in clinical studies. The poor imaging characteristics of 131I have resulted in the use of alternative radionuclides for radiolabelling monoclonal antibodies. Clinical imaging studies have shown that, in addition to the more suitable energy of emission of 111In over 13...

Pimm, M.V.; Perkins, A.C.; Baldwin, R.W., 1985: Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody ii. biodistribution studies in mice with human tumor xenografts. The blood, tumour and whole-body levels and survivals of 131I- and 111In-labelled monoclonal antibody (791T/36) have been compared in mice with human tumour xenografts. The blood levels and survivals of 131I- and 111In-labelled antibody were simil...

Pimm, M.V.; Perkins, A.C.; Baldwin, R.W., 1985: Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts. The blood, tumour and whole-body levels and survivals of 131I- and 111In-labelled monoclonal antibody (791T/36) have been compared in mice with human tumour xenografts. The blood levels and survivals of 131I- and 111In-labelled antibody were simil...

Motta-Hennessy, C.; Sharkey, R.M.; Goldenberg, D.M., 1990: Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. We have studied the fate of radiometal metabolism in vivo by analyzing the molecular form of radiolabeled anti-carcinoembryonic antigen (CEA) in tissues. Athymic mice bearing colonic tumor xenografts were injected i.v. with 111In-isothiocyanate-be...

Philben, V.J.; Jakowatz, J.G.; Beatty, B.G.; Vlahos, W.G.; Paxton, R.J.; Williams, L.E.; Shively, J.E.; Beatty, J.D., 1986: The effect of tumor CEA content and tumor size on tissue uptake of indium 111-labeled anti-CEA monoclonal antibody. This study was undertaken to determine the effect of tumor size and tumor carcinoembryonic antigen (CEA) content on the uptake of indium 111 (111In)-labeled anti-CEA monoclonal antibody in nude mice bearing xenografts. The tumor cell lines were Wi...

Reilly, R.M.; Thiessen, J.J., 1992: Mean time parameters reveal differences in the pharmacokinetics of indium-111 and iodine-131-labeled B72.3 monoclonal antibody. Journal of Nuclear Medicine 33(12): 2248-2250

Naruki Y.; Carrasquillo J.A.; Maloney P.; Reynolds J.C.; Frinke J.M.; Larson S.M., 1987: In vitro differences in metabolism of indium 111 yttrium 90 and iodine 125 labeled t101 monoclonal antibody. Journal of Nuclear Medicine 28(4 SUPPL): 693

Vuillez J P.; Peltier P.; Mayer J C.; Dubois F.; Chetanneau A.; Fumoleau P.; Bertrand A.; Chatal J F., 1990: Reproducibility of image interpretation in labeled immunoscintigraphy performed with indium 111 labeled and iodine 131 labeled oc 125 fab2 antibody injected into the same patients. European Journal of Nuclear Medicine 16(7): 452

Philben V.J.; Jakowatz J.G.; Beatty B.G.; Vlahos W.G.; Paxton R.J.; Williams L.E.; Shively J.E.; Beatty J.D., 1986: The effect of tumor carcinoembryonic antigen content and tumor size on tissue uptake of indium 111 labeled anti carcinoembryonic antigen monoclonal antibody. Cancer 57(3): 571-576

Ezekowitz M.D.; Srivastava S.C.; Meinkin G.E.; Smith E.O.; Scudder L.E.; Coller B., 1985: Thrombus detection in the canine model using iodine 131 labeled and indium 111 labeled antiplatelet monoclonal antibody. American Heart Association Monograph (114): III-467